حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Natco Pharma Limited
NATCOPHARMNATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India. Address: Natco House, Hyderabad, India, 500034
Analytics
سعر الهدف في وول ستريت
113 397.63 INRنسبة السعر إلى الأرباح
12.6742العائد الربحي
0.4 %السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية NATCOPHARM
تحليلات الأرباح NATCOPHARM
نمو الأرباح على مدى 5 سنوات
12 %النمو المستمر
2 سنينمعدل الدفع 5 سنوات في المتوسط
32 %تاريخ الأرباح NATCOPHARM
تقييم الأسهم NATCOPHARM
المالية NATCOPHARM
نتائج | 2019 | ديناميات |